Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation

Oral fixed-dose niacin extended release/simvastatin is associatedwith clinically relevant improvements in plasma lipid profiles, including lowering of nonhigh- density lipoprotein cholesterol levels, relative to simvastatinmonotherapy in patients with mixed dyslipidemias who had not responded fully...

Descripción completa

Detalles Bibliográficos
Autor principal: Lyseng-Williamson, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Drug and Profile Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586144/
https://www.ncbi.nlm.nih.gov/pubmed/21171671
http://dx.doi.org/10.2165/11202560-000000000-00000
_version_ 1782261275894480896
author Lyseng-Williamson, Katherine A.
author_facet Lyseng-Williamson, Katherine A.
author_sort Lyseng-Williamson, Katherine A.
collection PubMed
description Oral fixed-dose niacin extended release/simvastatin is associatedwith clinically relevant improvements in plasma lipid profiles, including lowering of nonhigh- density lipoprotein cholesterol levels, relative to simvastatinmonotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.
format Online
Article
Text
id pubmed-3586144
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-35861442013-03-07 Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation Lyseng-Williamson, Katherine A. Drugs R D Drug and Profile Report Oral fixed-dose niacin extended release/simvastatin is associatedwith clinically relevant improvements in plasma lipid profiles, including lowering of nonhigh- density lipoprotein cholesterol levels, relative to simvastatinmonotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated. Springer International Publishing 2012-11-25 2010-11 /pmc/articles/PMC3586144/ /pubmed/21171671 http://dx.doi.org/10.2165/11202560-000000000-00000 Text en © Adis Data Information BV 2010
spellingShingle Drug and Profile Report
Lyseng-Williamson, Katherine A.
Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title_full Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title_fullStr Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title_full_unstemmed Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title_short Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
title_sort niacin extended release (er)/simvastatin (simcor®): a guide to its use in lipid regulation
topic Drug and Profile Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586144/
https://www.ncbi.nlm.nih.gov/pubmed/21171671
http://dx.doi.org/10.2165/11202560-000000000-00000
work_keys_str_mv AT lysengwilliamsonkatherinea niacinextendedreleaseersimvastatinsimcoraguidetoitsuseinlipidregulation

Ejemplares similares